Market news

Elizabeth Yeu Lin, Chief Medical Officer, on September 04, 2026, sold 13,953 shares in Tarsus Pharma

Seshadri Neervannan, Chief Operating Officer, on September 04, 2026, sold 4,564 shares in Tarsus Pha

Tarsus Pharmaceuticals (TARS) said Friday that it has completed its acquisition of retinal disease-f

IRVINE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to attend ...

Tarsus Pharmaceuticals stock has delivered a very large 3 year return, yet the broader valuation checks still suggest it trades on the cheap side. Recent news around acquisitions and pipeline expansion adds another layer for investors trying to judge whether the current price fairly reflects the fundamentals. Over the past 3 years the share price has returned about 3.2x, which puts extra focus on whether that move is grounded in underlying value. The acquisition of Alkeus Pharmaceuticals and...

Detailed price information for Amn Healthcare Services Inc (AMN-N) from The Globe and Mail including charting and trades.

Alongside Alkeus, several companies like Belite Bio, Ocugen and Nanoscope are aiming to secure a place on the Stargardt market where there are no approved therapies.

Strong commercial momentum drives raised guidance as Tarsus positions for a diversified ophthalmology portfolio.

Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of -104.76% and +5.01%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

IRVINE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (“Tarsus”) today announced that it has entered into a securities purchase agreement with certain qualified institutional buyers and accredited...

Adds a potential blockbuster opportunity with gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the...

IRVINE, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 5:00 a.m. PT / 8:00 a.m. ET on Thursday, August 6, 2026 to report its second quarter 2026 financial results and provide a corporate update. Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days. About Tar

Tarsus Pharmaceuticals (TARS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tarsus Pharmaceuticals (NasdaqGS:TARS) announced the departure of its Chief Commercial Officer. The company appointed an interim commercial leader to oversee ongoing operations. Tarsus is engaged in M&A discussions with iRenix Medical. Tarsus Pharmaceuticals focuses on treatments in ophthalmology and related areas, which puts execution around commercial plans at the center of the story for many investors. A change in the Chief Commercial Officer role, combined with an interim appointment,...

Detailed price information for Unitedhealth Group (UNH-N) from The Globe and Mail including charting and trades.

Detailed price information for Tarsus Pharmaceuticals Inc (TARS-Q) from The Globe and Mail including charting and trades.

IRVINE, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that Aziz Mottiwala, Chief Commercial Officer, is departing the Company to pursue a new opportunity as Chief Executive Officer of a public medical device company. Effective immediately, Neera Clase, formerly Senior Vice President of Market Access, will serve as Interim Chief Commercial Officer while Tarsus conducts a search for a permanent successor. Since joining Tarsus in 2021, Ms. Cla

Tarsus Pharmaceuticals (NASDAQ:TARS) said it has closed its acquisition of iRenix Medical, Inc., adding IRX-101, a late-stage investigational ocular surface antiseptic, to its pipeline as the company seeks to expand its presence in eye care and enter the retina market. On an investor call discussin

IRX-101 targets a significant need for millions of patients facing vision loss and has the potential to improve the standard of care Positive Phase 2b/3 data and an FDA-aligned Phase 3 program provide a clear and near-term path forward; transaction structured to align economics with future value creation Tarsus to host investor conference call today, July 8, 2026, at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today an

Tarsus Pharmaceuticals (TARS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Tarsus Pharmaceuticals (TARS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.